Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.

Articles in this issue

---

ASH 2020: Clinical Updates

ASH 2020: COVID-19 and Hematology

ASH 2020: CAR T-Cell Therapy Updates

ASH 2020: The Next Wave

2020 SABCS: Topics in Precision Oncology

Lauren M. Corduck, Founder of Oneinforty, Dies at 49; Advocated for Change in BRCA Testing Guidelines

Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Related Videos

Related Content

Advertisement

December 17th 2024

Top 5 Most-Read Breast Cancer Articles of 2024

Cameron Santoro

The most-read breast cancer articles include topics on hereditary breast cancer, hormone therapy benefits, BRCA mutations, as well as treatment outcomes.

October 30th 2023

Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening

Pearl Steinzor

On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.

December 11th 2024

Elacestrant Shows Real-World Effectiveness in Metastatic Breast Cancers

Cameron Santoro

Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction in disease progression or death compared with standard-of-care endocrine therapy.

February 22nd 2022

The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer

On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.

November 23rd 2024

Age-Related Disparities in Long-Term Outcomes for ER+, HER2– Breast Cancer

Cameron Santoro

Younger women with estrogen receptor (ER)–positive, HER2-negative breast cancer have significantly worse long-term outcomes, including higher rates of recurrence and metastasis, compared with older women.

November 19th 2024

Racial Inequities in Guideline-Adherent Breast Cancer Care and Timely Treatment

Cameron Santoro

Older non-Hispanic Black adults with early-stage breast cancer are less likely to receive timely treatment and guideline-concordant care, increasing their risk of death compared with non-Hispanic White women.

Related Content

Advertisement

December 17th 2024

Top 5 Most-Read Breast Cancer Articles of 2024

Cameron Santoro

The most-read breast cancer articles include topics on hereditary breast cancer, hormone therapy benefits, BRCA mutations, as well as treatment outcomes.

October 30th 2023

Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening

Pearl Steinzor

On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.

December 11th 2024

Elacestrant Shows Real-World Effectiveness in Metastatic Breast Cancers

Cameron Santoro

Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction in disease progression or death compared with standard-of-care endocrine therapy.

February 22nd 2022

The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer

On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.

November 23rd 2024

Age-Related Disparities in Long-Term Outcomes for ER+, HER2– Breast Cancer

Cameron Santoro

Younger women with estrogen receptor (ER)–positive, HER2-negative breast cancer have significantly worse long-term outcomes, including higher rates of recurrence and metastasis, compared with older women.

November 19th 2024

Racial Inequities in Guideline-Adherent Breast Cancer Care and Timely Treatment

Cameron Santoro

Older non-Hispanic Black adults with early-stage breast cancer are less likely to receive timely treatment and guideline-concordant care, increasing their risk of death compared with non-Hispanic White women.